<?xml version='1.0' encoding='utf-8'?>
<document id="24188100"><sentence text="Targeting the Janus kinases in rheumatoid arthritis: focus on tofacitinib."><entity charOffset="62-73" id="DDI-PubMed.24188100.s1.e0" text="tofacitinib" /></sentence><sentence text="Treatment of rheumatoid arthritis (RA) has markedly advanced by the advent of biologic disease-modifying antirheumatic drugs (DMARDs)" /><sentence text=" However, they require special storage and transportation and remission is observed in âˆ¼ 30%" /><sentence text=" Tofacitinib inhibits the nonreceptor tyrosine kinase family Janus kinase (JAK), which is activated immediately after cytokines bind to their receptor within the cytoplasmic membrane"><entity charOffset="1-12" id="DDI-PubMed.24188100.s4.e0" text="Tofacitinib" /><entity charOffset="38-46" id="DDI-PubMed.24188100.s4.e1" text="tyrosine" /><pair ddi="false" e1="DDI-PubMed.24188100.s4.e0" e2="DDI-PubMed.24188100.s4.e0" /><pair ddi="false" e1="DDI-PubMed.24188100.s4.e0" e2="DDI-PubMed.24188100.s4.e1" /></sentence><sentence text="" /><sentence text="Tofacitinib is an orally available tablet and treatment efficacy is similar to biologic DMARDs"><entity charOffset="0-11" id="DDI-PubMed.24188100.s6.e0" text="Tofacitinib" /></sentence><sentence text=" Pharmacokinetics, and drug-drug interaction is covered in this article" /><sentence text=" In addition, efficacy and adverse events from the Phase II and Phase III are overviewed" /><sentence text=" Additionally, the authors have described the novel mechanism of action (MOA) of tofacitinib in relevance to efficacy and adverse events"><entity charOffset="81-92" id="DDI-PubMed.24188100.s9.e0" text="tofacitinib" /></sentence><sentence text=" Because of its MOA, greater caution is necessary for selecting appropriate patients for treatment initiation and further treatment continuation following clinical trials" /><sentence text="" /><sentence text="Tofacitinib is a new class of DMARDs orally available with a new mechanism of action and with strong clinical efficacy similar to biologic DMARDs"><entity charOffset="0-11" id="DDI-PubMed.24188100.s12.e0" text="Tofacitinib" /><entity charOffset="30-36" id="DDI-PubMed.24188100.s12.e1" text="DMARDs" /><pair ddi="false" e1="DDI-PubMed.24188100.s12.e0" e2="DDI-PubMed.24188100.s12.e0" /><pair ddi="false" e1="DDI-PubMed.24188100.s12.e0" e2="DDI-PubMed.24188100.s12.e1" /></sentence><sentence text=" Multiple cytokines and signaling pathways are partially inhibited at clinical doses that are in contrast to biological DMARDs" /><sentence text=" Further investigation is necessary to come to a conclusion on risk-benefit ratio and selection of patients" /><sentence text="" /></document>